tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 275 are a BUY (85.94%), 44 are a HOLD (13.75%), 1 are a SELL (0.31%).
Analyst Robyn Karnauskas, currently employed at TRUIST, carries an average stock price target met ratio of 50.9% that have a potential upside of 38.99% achieved within 274 days.
Robyn Karnauskas’s has documented 651 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MRK, Merck mpany at 07-Nov-2024.
Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$206
$23.2 (12.69%)
$153
10 days ago
(22-Nov-2024)
13/14 (92.86%)
$27.92 (15.68%)
293
Buy
$205
$22.2 (12.14%)
17 days ago
(15-Nov-2024)
2/3 (66.67%)
$39.27 (23.70%)
507
Buy
$200
$17.2 (9.41%)
$190
19 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Buy
$224
$41.2 (22.54%)
$231
20 days ago
(12-Nov-2024)
12/15 (80%)
$48.86 (27.90%)
488
Buy
$215
$32.2 (17.61%)
$226
20 days ago
(12-Nov-2024)
8/10 (80%)
$39.86 (22.76%)
293
Which stock is Robyn Karnauskas is most bullish on?
Which stock is Robyn Karnauskas is most reserved on?
What Year was the first public recommendation made by Robyn Karnauskas?
